Customer Publication
Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer advantages for targeted cancer therapies
Journal: Cancer Research (2021)
Institution: Max Planck Institute for Medical Research, Heidelberg
Research Areas: Cytotoxicity
Cell Lines: LNCaP and 22Rv1 (LNCaP – androgen-sensitive human prostate adenocarcinoma cell line; 22Rv1 – prostate carcinoma epiithelial cell line)
Summary: The metastatic, castration-resistant prostate cancer represents a major therapeutic challenge as treatment options are limited to only a few options, such as prostate-specific membrane antigen (PSMA) inhibitors. However, the detailed understanding of the mode of action inside the cells and the internalization mechanism of these molecules are still unknown. In this publication, J. Matthias with colleagues have synthesized a fluorescence-labeled PMSA inhibitors and elucidated their uptake mechanism and fate inside the cell using STED nanoscopy. HoloMonitor M4 was used to evaluate fluorescence molecule cytotoxicity and revealed that they do not affect cell proliferation.